Education
About Us
Working with TipRanks
Follow Us
Rigel (RIGL)
NASDAQ:RIGL
Earnings Data
Report Date
Nov 06, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
0.9Last Year’s EPS
0.7Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a robust and positive second quarter for Rigel Pharmaceuticals, with significant revenue growth and strong commercial performance across their product portfolio. The company has raised its revenue guidance for 2025, indicating confidence in continued growth. Financial discipline has led to increased profitability, and the development pipeline shows promise. The lowlight identified is minor, involving a change in patient response status in a clinical study.Company Guidance -
Q3 2025
Record-Breaking Revenue and Growth
Rigel Pharmaceuticals achieved net product sales of more than $58 million, an increase of 76% year-over-year, marking their best quarter ever. Total revenue for the second quarter was $101.7 million, driven by their growing commercial portfolio and increased sales across all commercial products.
Strong Commercial Performance
The commercial portfolio, including TAVALISSE, GAVRETO, and REZLIDHIA, showed strong year-over-year growth. TAVALISSE net product sales increased by 52% compared to Q2 2024, GAVRETO delivered $11.8 million in net product sales (a significant growth since its late June 2024 introduction), and REZLIDHIA saw a 36% increase compared to the prior year period.
Increased Revenue Guidance for 2025
Rigel raised their total revenue guidance for 2025 to between $270 million and $280 million, up from the previous range of $200 million to $210 million. Net product sales expectations were also increased to $210 million to $220 million.
Successful Financial Discipline and Profitability
Rigel generated $59.6 million in net income in the second quarter and increased their cash balance to more than $108 million. They continue to anticipate reporting positive net income for the full year 2025.
Promising Development Pipeline
Rigel's R289, a novel dual IRAK1/4 inhibitor, is progressing well with completed enrollment in the dose escalation part of a Phase 1b clinical study. Ocadusertib, under development with Eli Lilly, is also advancing successfully.
RIGL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RIGL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 05, 2025 | $24.24 | $29.81 | +22.98% |
May 06, 2025 | $18.26 | $18.47 | +1.15% |
Mar 04, 2025 | $22.08 | $20.29 | -8.11% |
Nov 07, 2024 | $15.44 | $22.07 | +42.94% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Rigel (RIGL) report earnings?
Rigel (RIGL) is schdueled to report earning on Nov 06, 2025, After Close (Confirmed).
What is Rigel (RIGL) earnings time?
Rigel (RIGL) earnings time is at Nov 06, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RIGL EPS forecast?
RIGL EPS forecast for the fiscal quarter 2025 (Q3) is 0.9.